In hepatocellular carcinoma (HCC), sorafenib resistance is induced by the delivery of hepatocyte growth factor (HGF) through EVs, which activates the HGF/c-MET/PI3K/AKT signaling pathway. This evidence concerns the gene MET and hepatocellular carcinoma.